Johnson & Johnson (NYSE:JNJ) Shares Sold by JFS Wealth Advisors LLC

JFS Wealth Advisors LLC lowered its position in Johnson & Johnson (NYSE:JNJ) by 1.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 30,287 shares of the company’s stock after selling 334 shares during the quarter. JFS Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $4,380,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Knuff & Co LLC lifted its stake in shares of Johnson & Johnson by 0.7% during the third quarter. Knuff & Co LLC now owns 9,466 shares of the company’s stock worth $1,534,000 after purchasing an additional 64 shares in the last quarter. Vertex Planning Partners LLC lifted its stake in shares of Johnson & Johnson by 1.3% during the third quarter. Vertex Planning Partners LLC now owns 5,211 shares of the company’s stock worth $844,000 after purchasing an additional 65 shares in the last quarter. Freedom Day Solutions LLC lifted its stake in shares of Johnson & Johnson by 1.1% during the third quarter. Freedom Day Solutions LLC now owns 6,269 shares of the company’s stock worth $1,016,000 after purchasing an additional 66 shares in the last quarter. Traphagen Investment Advisors LLC lifted its stake in shares of Johnson & Johnson by 0.6% during the third quarter. Traphagen Investment Advisors LLC now owns 10,483 shares of the company’s stock worth $1,699,000 after purchasing an additional 67 shares in the last quarter. Finally, Corepath Wealth Partners LLC lifted its stake in shares of Johnson & Johnson by 3.7% during the fourth quarter. Corepath Wealth Partners LLC now owns 1,985 shares of the company’s stock worth $287,000 after purchasing an additional 70 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Activity

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on JNJ. Barclays boosted their price objective on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Tuesday, January 28th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Citigroup cut their price target on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Leerink Partners cut their price target on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Finally, Raymond James cut their price target on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $170.67.

Johnson & Johnson Stock Up 1.9 %

NYSE:JNJ opened at $157.93 on Thursday. The firm has a market capitalization of $380.23 billion, a PE ratio of 23.75, a price-to-earnings-growth ratio of 2.50 and a beta of 0.52. The stock has a 50 day moving average of $148.34 and a 200-day moving average of $155.86. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business’s revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the company earned $2.29 earnings per share. Analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.14%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.